SPRO - Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2 ^nd Annual BioConnect Investor Conference at NASDAQ , to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:

The webcast may also be accessed through Spero Therapeutics’ website ( www.sperotherapeutics.com ) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.

• Spero Therapeutics is developing its wholly owned lead product candidate, SPR720 as a novel oral, first-line treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD), currently advancing in a Phase 2A proof of concept study. NTM-PD is a rare pulmonary disease caused by non-tuberculous mycobacterial infections.

• Tebipenem HBr is an investigational oral drug advancing in a Phase 3 registrational trial for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories.

• SPR206 is an innovative, investigational IV-administered direct-acting next generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies. An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.
  

For more information, visit https://sperotherapeutics.com .

Investor Relations Contact:
Ashley R. Robinson Managing Director, LifeSci Advisors, LLC
arr@lifesciadvisors.com
(617) 775-5956

Media Inquiries: media@sperotherapeutics.com